ClinicalTrials.gg
Active, not recruitingNCT06672445Updated Jun 29, 2026

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

A Phase 1 interventional study of ARO-ATXN2 Injection and Placebo in Spinocerebellar Ataxia Type 2, sponsored by Arrowhead Pharmaceuticals. Active, not recruiting at 16 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Arrowhead Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

02

Conditions studied

  • Spinocerebellar Ataxia Type 2
03

In context

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

This study's enrollment of 39 is above the median of 29 across 61 interventional studies indexed under Spinocerebellar Ataxias.

Browse Spinocerebellar Ataxias studies →

Lead sponsor

Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pregnant, non-lactating
  • Diagnosis of symptomatic SCA2 and ≥33 CAG repeats in the ATXN2 gene based on source verifiable medical records or genetic testing at Screening
  • Scale of Assessment and Rating of Ataxia (SARA) score ≤14
  • Subjects of must agree to use highly effective in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Subjects must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension (blood pressure >160/100 mmHg)
  • History of having received stem cell therapy
  • cardiac, liver, or renal disease
  • (HIV) infection (seropositive at Screening)
  • Seropositive for (HBV) or (HCV) at Screening
  • Intellectual disability or significant behavioral neuropsychiatric manifestation
  • Any to lumbar puncture, including >1.4, count \<100,000, and use of anticoagulant or antiplatelet medications that cannot be safely interrupted
  • Presence of an implanted shunt for drainage of CSF or an implanted central nervous system (CNS) catheter

Note: Additional inclusion/exclusion criteria may apply per protocol.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    ARO-ATXN2

    ARO-ATXN2 Injection

    Drug: ARO-ATXN2 Injection

  • Placebo comparator
    Placebo

    (0.9% NaCl)

    Drug: Placebo

Interventions

  • DrugARO-ATXN2 Injection

    single dose of ARO-ATXN2 by intrathecal (IT) administration

  • DrugPlacebo

    calculated volume to match active treatment by IT administration

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment -Emergent Adverse Events (TEAEs) Over Time

    Time frame: Through End of Study (EOS), Day 253

Secondary outcomes

  1. Pharmacokinetics (PK) of ARO-ATXN2: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Through 24 hours post-dose

  2. PK of ARO-ATXN2: Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Through 24 hours post-dose

  3. PK of ARO-ATXN2: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)

    Time frame: Through 24 hours post-dose

  4. PK of ARO-ATXN2: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Quatifiable Plasma Concentration (AUClast)

    Time frame: Through 24 hours post-dose

  5. PK of ARO-ATXN2: Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUCinf)

    Time frame: Through 24 hours post-dose

  6. PK of ARO-ATXN2: Elimination Half-life (t1/2)

    Time frame: Through 24 hours post-dose

  7. PK of ARO-ATXN2: Apparent Systemic Clearance (CL/F)

    Time frame: Through 24 hours post-dose

  8. PK of ARO-ATXN2: Recovery of Unchanged Drug Excreted in Urine (Ae)

    Time frame: Through 24 hours post-dose

  9. PK of ARO-ATXN2: Renal Clearance (CLr)

    Time frame: Through 24 hours post-dose

  10. Percentage of Administered Drug Recovered in Urine

    Time frame: Through 24 hours post-dose

  11. Change from Baseline in Total Protein in Cerebral Spinal Fluid (CSF) Over Time

    Time frame: Baseline through End of Study (EOS), Day 253

  12. Change from Baseline in Glucose in CSF Over Time

    Time frame: Baseline through End of Study (EOS), Day 253

  13. Change from Baseline in Cell Count in CSF Over Time

    Time frame: Baseline through End of Study (EOS), Day 253

07

Study locations

16 sites
  • Research Site 8
    Sydney, New South Wales 2170, Australia
  • Research Site 7
    Melbourne, Victoria 3004, Australia
  • Research Site 2
    Montreal, Quebec H2X 0C1, Canada
  • Research Site 1
    Montreal, Quebec H3A 2B4, Canada
  • Research Site 9
    Edmonton, 8440, Canada
  • Research Site 15
    Paris, 75651, France
  • Research Site 13
    Tübingen, Baden-Wurttemberg 72026, Germany
  • Research Site 14
    Ulm, Baden-Wurttemberg 89081, Germany
  • Research Site 16
    Milan, 20133, Italy
  • Research Site 4
    Auckland, 0622, New Zealand
  • Research Site 3
    Christchurch, 8011, New Zealand
  • Research Site 10
    Barcelona, 08035, Spain
  • Research Site 11
    Barcelona, 08036, Spain
  • Research Site 12
    Seville, 41013, Spain
  • Research Site 5
    Kaohsiung City, 833401, Taiwan
  • Research Site 6
    Taipei, 112201, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672445
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Dec 17, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion